Schwarz files Parkinson’s patch
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schwarz' Sept. 29 submission of Neupro (rotigotine) for treatment of early-stage Parkinson's disease is the generic firm's first attempt at the new drug market. The transdermal rotigotine patch is "the first submission of a novel new chemical entity from our…pipeline," the company says. Rotigotine is a non-ergot dopamine D2 agonist; Schwarz licensed the product from Aderis in 1998. Phase III studies in late-stage PD are ongoing, with an NDA projected for first-quarter 2006. A nasal spray rotigotine formulation is in Phase I studies for acute PD...
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.